CELGENE CORP /DE/
CELGENE CORP /DE/ (CELG): 9 pipeline candidates · ~17 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
17.0 months
D/E 2.42
Lead: Approved
9 candidates
N/A
N/A
A transparent, data-derived signal for CELGENE CORP /DE/across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$9.6B
Quarterly Burn
$1.9B
Runway
17.0 mo
Revenue
$4.5B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| bb2121 | Phase 3 |
| fedratinib | BLA Filed |
| fludarabine | Phase 3 |
| iberdomide | Phase 2 |
| idecabtagene vicleucel | Phase 3 |
| liso-cel | Phase 3 |
| luspatercept | Phase 3 |
| ozanimod | Phase 3 |
| thalomid | Approved |
Frequently asked questions
How many drug candidates are in CELGENE CORP /DE/'s pipeline?
CELGENE CORP /DE/ (CELG) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CELGENE CORP /DE/'s lead drug candidate?
CELGENE CORP /DE/'s most advanced tracked candidate is bb2121 (Phase 3) for relapsed and/or refractory multiple myeloma (RRMM).
What is CELGENE CORP /DE/'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CELGENE CORP /DE/ has approximately 17.0 months of cash runway.
Get the full picture on CELGENE CORP /DE/
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.